Financiere des Professionnels Fonds d investissement inc. Grows Stake in Gilead Sciences, Inc. $GILD

Financiere des Professionnels Fonds d investissement inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,350 shares of the biopharmaceutical company’s stock after acquiring an additional 4,402 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.’s holdings in Gilead Sciences were worth $4,584,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ares Financial Consulting LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $28,000. Financial Consulate Inc. boosted its stake in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares during the last quarter. North Star Investment Management Corp. boosted its stake in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 86 shares during the last quarter. BOCHK Asset Management Ltd purchased a new position in Gilead Sciences in the fourth quarter valued at about $31,000. Finally, Godfrey Financial Associates Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $34,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive Phase 3 results for a once-weekly HIV regimen using islatravir and lenacapavir, a potential advance that could strengthen Gilead’s already important HIV franchise and support long-term revenue growth. Article Title
• Positive Sentiment: Analysts and recent commentary pointed to momentum in Gilead’s HIV portfolio, including strength in Biktarvy and Descovy, as well as improving expectations for Yeztugo and other late-stage pipeline assets. Article Title
• Positive Sentiment: Gilead said topline Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis showed significantly more patients reached key treatment goals, which could broaden the company’s pipeline and add another growth driver. Article Title
• Neutral Sentiment: Gilead presented at the Goldman Sachs Global Healthcare Conference, which likely reinforced management’s pipeline and growth narrative but did not appear to include a major new catalyst. Article Title
• Negative Sentiment: Gilead and Merck also ended a Phase 3 lung cancer study after Trodelvy plus KEYTRUDA failed to deliver a statistically significant improvement, renewing concern around Gilead’s oncology strategy. Article Title
• Negative Sentiment: Biopharma coverage noted that the Trodelvy setback creates risk for one of Gilead’s key cancer programs, even as HIV progress remains the bigger driver for the stock. Article Title

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the sale, the chief executive officer directly owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock valued at $9,047,570 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Leerink Partners decreased their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Gilead Sciences in a report on Monday. Needham & Company LLC reissued a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Mizuho lifted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $121.48 on Thursday. The company has a 50 day moving average of $133.73 and a 200 day moving average of $134.34. The stock has a market cap of $150.83 billion, a P/E ratio of 16.55 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.